From Xenon to Hovione
04.09.2012 - Portuguese API specialist Hovione (Loures) has named Dr. Conrad Winters as new Drug Product Development Director.
Dr Winters was previously with Merck in the USA and Canada and most recently with Xenon Pharmaceuticals Inc., where he held the position of Senior Director, Compound Properties Group. The pharmacist brings 18 years of experience in the pharmaceutical industry with a focus on managing the development of compounds from lead candidate optimisation to NDA submission and commercialisation. He has extensive experience in rational formulation design, based on fundamental understanding of material properties and the adaptation of particle properties to effect improved bioperformance. Winters has led cross functional global teams charged with the development of priority new chemical entities. He has contributed to and prepared documentation in support of many successful regulatory submissions.